JP2004523538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004523538A5 JP2004523538A5 JP2002562389A JP2002562389A JP2004523538A5 JP 2004523538 A5 JP2004523538 A5 JP 2004523538A5 JP 2002562389 A JP2002562389 A JP 2002562389A JP 2002562389 A JP2002562389 A JP 2002562389A JP 2004523538 A5 JP2004523538 A5 JP 2004523538A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- therapeutic agent
- agent according
- ischemic stroke
- humans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0103174.9 | 2001-02-08 | ||
| GBGB0103174.9A GB0103174D0 (en) | 2001-02-08 | 2001-02-08 | Novel method of treatment |
| PCT/GB2002/000551 WO2002062383A2 (en) | 2001-02-08 | 2002-02-08 | Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008137916A Division JP2008291031A (ja) | 2001-02-08 | 2008-05-27 | 新規治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004523538A JP2004523538A (ja) | 2004-08-05 |
| JP2004523538A5 true JP2004523538A5 (https=) | 2005-12-22 |
| JP5005156B2 JP5005156B2 (ja) | 2012-08-22 |
Family
ID=9908386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562389A Expired - Fee Related JP5005156B2 (ja) | 2001-02-08 | 2002-02-08 | 新規治療方法 |
| JP2008137916A Ceased JP2008291031A (ja) | 2001-02-08 | 2008-05-27 | 新規治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008137916A Ceased JP2008291031A (ja) | 2001-02-08 | 2008-05-27 | 新規治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20040170627A1 (https=) |
| EP (2) | EP1357941B1 (https=) |
| JP (2) | JP5005156B2 (https=) |
| AT (1) | ATE314861T1 (https=) |
| AU (1) | AU2002229928A1 (https=) |
| CY (1) | CY1105549T1 (https=) |
| DE (1) | DE60208534T2 (https=) |
| DK (1) | DK1357941T3 (https=) |
| ES (1) | ES2254655T3 (https=) |
| GB (1) | GB0103174D0 (https=) |
| WO (1) | WO2002062383A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0103174D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Plc | Novel method of treatment |
| US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
| TWI323265B (en) | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| GB0306309D0 (en) * | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Method of treatment |
| EP3514238B1 (en) * | 2003-05-16 | 2021-05-05 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
| US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
| AU2003300896A1 (en) * | 2003-12-10 | 2005-07-14 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use |
| JP5189985B2 (ja) | 2005-09-26 | 2013-04-24 | アコーダ セラピューティクス、インク． | コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法 |
| WO2009009406A1 (en) * | 2007-07-06 | 2009-01-15 | Smithkline Beecham Corporation | Antibody formulations |
| US8974782B2 (en) | 2011-02-07 | 2015-03-10 | Glaxo Group Limited | Treatment of stroke comprising anti-MAG antibodies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5250414A (en) * | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| GB9403250D0 (en) * | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
| US6576607B1 (en) * | 1995-04-19 | 2003-06-10 | Acorda Therapeutics | Methods using CNS neurite outgrowth modulators |
| US5792743A (en) * | 1995-04-19 | 1998-08-11 | Acorda Therapeutics | Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule |
| ATE275415T1 (de) * | 1995-06-27 | 2004-09-15 | Res Foundation Of Cuny Hunter | Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält |
| JP2001521008A (ja) * | 1997-10-28 | 2001-11-06 | ユニバーシティ・オブ・ブリティッシュ・コロンビア | 哺乳類の中枢神経系ミエリンを一過的に変えて神経再生を促進する免疫組成物及びその使用方法 |
| BR9815289A (pt) * | 1997-11-14 | 2001-12-26 | Euro Celtique Sa | Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado |
| AU3134799A (en) * | 1998-04-16 | 1999-11-08 | Peter Erich Braun | Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration |
| GB9908533D0 (en) * | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| GB0103174D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Plc | Novel method of treatment |
| US20040002790A1 (en) * | 2002-06-28 | 2004-01-01 | Paul Senn | Sensitive devices and sensitive applications |
| TWI323265B (en) * | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| GB0306309D0 (en) * | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Method of treatment |
-
2001
- 2001-02-08 GB GBGB0103174.9A patent/GB0103174D0/en not_active Ceased
-
2002
- 2002-02-08 WO PCT/GB2002/000551 patent/WO2002062383A2/en not_active Ceased
- 2002-02-08 DE DE60208534T patent/DE60208534T2/de not_active Expired - Lifetime
- 2002-02-08 DK DK02711034T patent/DK1357941T3/da active
- 2002-02-08 AT AT02711034T patent/ATE314861T1/de active
- 2002-02-08 ES ES02711034T patent/ES2254655T3/es not_active Expired - Lifetime
- 2002-02-08 AU AU2002229928A patent/AU2002229928A1/en not_active Abandoned
- 2002-02-08 EP EP02711034A patent/EP1357941B1/en not_active Expired - Lifetime
- 2002-02-08 JP JP2002562389A patent/JP5005156B2/ja not_active Expired - Fee Related
- 2002-02-08 EP EP05077130A patent/EP1645285A3/en not_active Withdrawn
- 2002-02-08 US US10/467,253 patent/US20040170627A1/en not_active Abandoned
-
2006
- 2006-02-01 CY CY20061100125T patent/CY1105549T1/el unknown
-
2007
- 2007-05-09 US US11/746,355 patent/US20080014195A1/en not_active Abandoned
-
2008
- 2008-05-27 JP JP2008137916A patent/JP2008291031A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020003I1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
| JP2019518742A5 (https=) | ||
| JP2022031635A5 (https=) | ||
| TR200102733T2 (tr) | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
| ATE471946T1 (de) | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 | |
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| JP2007051159A5 (https=) | ||
| JP2008538564A5 (https=) | ||
| ATE437655T1 (de) | Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper | |
| DE05075555T1 (de) | Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern | |
| ATE364699T1 (de) | Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen | |
| NZ605429A (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
| ATE454124T1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
| JP2004523538A5 (https=) | ||
| DE69229482D1 (de) | Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor | |
| JP2002506648A5 (https=) | ||
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| WO2004108766A3 (en) | Anti-hgf-r antibodies and their use | |
| ATE407147T1 (de) | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein | |
| JP2004532885A5 (https=) | ||
| JP2020508074A5 (https=) | ||
| JP2004508415A5 (https=) | ||
| ES2061769T3 (es) | Anticuerpo monoclonal y su utilizacion. | |
| EP1488806A3 (en) | A blocking monoclonal antibody to VLA-1 and its use for the treatment of vascular disorders | |
| JP2018529672A5 (https=) |